DexCom (DXCM) Rule 144 Notice: 667 Shares From Vesting to Be Sold

Rhea-AI Filing Summary

DexCom insider notification: A person affiliated with DexCom, Inc. (DXCM) indicated a proposed sale of 667 common shares through Fidelity Brokerage Services with an aggregate market value of $53,933.62. The filing lists approximately 392,155,265 shares outstanding and an approximate sale date of 09/05/2025. The securities were acquired on 05/18/2024 via restricted stock vesting and paid as compensation. The filer reports no securities sold in the past three months and makes the Rule 144 representation that they are not aware of undisclosed material adverse information about the issuer.

Positive

• Disclosure filed under Rule 144, demonstrating regulatory compliance and transparency
• No securities sold in the past three months, indicating this is an isolated transaction

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine insider disclosure of a small, vested equity sale; compliant with Rule 144 and includes standard representations.

The filing documents a planned sale of 667 shares received from restricted stock vesting and paid as compensation. The disclosure through Fidelity and the explicit representation about material nonpublic information align with standard compliance practices. No other dispositions in the prior three months are reported, which supports transparency around insider activity. Given the small absolute size relative to total outstanding shares, this appears administrative rather than governance-significant.

Securities Analyst

TL;DR: Economically immaterial sale by an insider; unlikely to affect market valuation or liquidity.

The seller plans to offer 667 common shares valued at $53,933.62 against 392,155,265 outstanding shares, representing a de minimis fraction of the float. The shares were acquired through restricted stock vesting on 05/18/2024 and classified as compensation, indicating this is a post-vesting monetization rather than a secondary sale from a large holder. The filing contains no reported recent sales to suggest ongoing large-scale dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	667	53933.62	392155265	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/18/2024	Restricted Stock Vesting	Issuer			667	05/18/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the DXCM Form 144 disclose?

It discloses a proposed sale of 667 common shares through Fidelity with an aggregate market value of $53,933.62 and an approximate sale date of 09/05/2025.

How were the shares acquired according to the filing?

The shares were acquired on 05/18/2024 via restricted stock vesting and the payment is listed as compensation.

Has the filer sold other DXCM shares recently?

The filing states Nothing to Report for securities sold during the past three months.

Through which broker will the sale occur?

The sale is to be executed through Fidelity Brokerage Services LLC at the address listed in the filing.

Does the filer claim any undisclosed material information?

By signing the notice, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.